This Week in Cardiology cover image

Apr 14 2023 This Week in Cardiology

This Week in Cardiology

00:00

The Disruption of the Diet Industry From Semaglutide and Terezepatide

The Wall Street Journal reported on the disruption in a weight loss market from semaglutide and terezepatide. These drugs are going to seriously disrupt the status quo aren't they? The question therefore is what will the diet industry do because if they embrace these drugs there's much less need to sell diet plans, meal plans, exercise programs etc. I think we're at the beginning of a new chapter and I don't know what will happen.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app